$LAHO ..Bioheart, Inc. (otcqb:BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group in Cozumel, Mexico. The two companies have successfully treated their first congestive heart failure patient at the new clinical site last week using Bioheart's AdipoCell (adipose derived stem cells).
Long before they were USR*, “BHR* (Market cap $3.6M) collaborated with GSCG for congested heart failure treatment with success! If we apply Shillers 30x multiple for health-tech sector @$100m sector....Dollar!
The Shiller P/E is a more reasonable market valuation indicator than the P/E ratio because it eliminates fluctuation of the ratio caused by the variation of profit margins during business cycles.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.